• +1-646-491-9876
    • +91-20-67278686

    Search

    Respiratory Syncytial Virus Infections-Pipeline Review H1 2017

    Respiratory Syncytial Virus Infections-Pipeline Review H1 2017

    • Report Code ID: RW0001834335
    • Category Pharmaceuticals
    • No. of Pages 250
    • Publication Month May-17
    • Publisher Name Global Markets Direct
    Respiratory Syncytial Virus (RSV) Infections - Pipeline Review, H1 2017

    Summary

    Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Respiratory Syncytial Virus (RSV) Infections - Pipeline Review, H1 2017, provides an overview of the Respiratory Syncytial Virus (RSV) Infections (Infectious Disease) pipeline landscape.

    Respiratory syncytial virus (RSV) infection is a respiratory disease. It infects the lungs and breathing passages. RSV commonly causes bronchiolitis (inflammation of the small airways in the lung) and pneumonia in children less than one year of age. The symptoms of RSV infection include cough, stuffy or runny nose, mild sore throat, earache and fever. Treatment includes proper medication and hygiene practice.

    Report Highlights

    Publisher's Pharmaceutical and Healthcare latest pipeline guide Respiratory Syncytial Virus (RSV) Infections - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Respiratory Syncytial Virus (RSV) Infections (Infectious Disease) , complete with analysis by stage of development, drug target, mechanism of action (MoA) , route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

    The Respiratory Syncytial Virus (RSV) Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Respiratory Syncytial Virus (RSV) Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 14, 13, 47 and 21 respectively. Similarly, the Universities portfolio in Phase I, Preclinical and Discovery stages comprises 7, 14 and 5 molecules, respectively.

    Respiratory Syncytial Virus (RSV) Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Scope

    - The pipeline guide provides a snapshot of the global therapeutic landscape of Respiratory Syncytial Virus (RSV) Infections (Infectious Disease) .
    - The pipeline guide reviews pipeline therapeutics for Respiratory Syncytial Virus (RSV) Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
    - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
    - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
    - The pipeline guide reviews key companies involved in Respiratory Syncytial Virus (RSV) Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.
    - The pipeline guide evaluates Respiratory Syncytial Virus (RSV) Infections (Infectious Disease) therapeutics based on mechanism of action (MoA) , drug target, route of administration (RoA) and molecule type.
    - The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
    - The pipeline guide reviews latest news related to pipeline therapeutics for Respiratory Syncytial Virus (RSV) Infections (Infectious Disease)

    Reasons to buy

    - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
    - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
    - Find and recognize significant and varied types of therapeutics under development for Respiratory Syncytial Virus (RSV) Infections (Infectious Disease) .
    - Classify potential new clients or partners in the target demographic.
    - Develop tactical initiatives by understanding the focus areas of leading companies.
    - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
    - Formulate corrective measures for pipeline projects by understanding Respiratory Syncytial Virus (RSV) Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
    - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
    Table of Contents 2
    Introduction 6
    Respiratory Syncytial Virus (RSV) Infections - Overview 7
    Respiratory Syncytial Virus (RSV) Infections - Therapeutics Development 8
    Respiratory Syncytial Virus (RSV) Infections - Therapeutics Assessment 23
    Respiratory Syncytial Virus (RSV) Infections - Companies Involved in Therapeutics Development 31
    Respiratory Syncytial Virus (RSV) Infections - Drug Profiles 60
    Respiratory Syncytial Virus (RSV) Infections - Dormant Projects 222
    Respiratory Syncytial Virus (RSV) Infections - Discontinued Products 225
    Respiratory Syncytial Virus (RSV) Infections - Product Development Milestones 226
    Appendix 237

    List of Tables

    Number of Products under Development for Respiratory Syncytial Virus (RSV) Infections, H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products under Development by Companies, H1 2017 (Contd..1) , H1 2017
    Number of Products under Development by Companies, H1 2017 (Contd..2) , H1 2017
    Number of Products under Development by Companies, H1 2017 (Contd..3) , H1 2017
    Number of Products under Development by Universities/Institutes, H1 2017
    Products under Development by Companies, H1 2017
    Products under Development by Companies, H1 2017 (Contd..1) , H1 2017
    Products under Development by Companies, H1 2017 (Contd..2) , H1 2017
    Products under Development by Companies, H1 2017 (Contd..3) , H1 2017
    Products under Development by Companies, H1 2017 (Contd..4) , H1 2017
    Products under Development by Universities/Institutes, H1 2017
    Products under Development by Universities/Institutes, H1 2017 (Contd..1) , H1 2017
    Number of Products by Stage and Target, H1 2017
    Number of Products by Stage and Mechanism of Action, H1 2017
    Number of Products by Stage and Route of Administration, H1 2017
    Number of Products by Stage and Molecule Type, H1 2017
    Respiratory Syncytial Virus (RSV) Infections - Pipeline by Abivax SA, H1 2017
    Respiratory Syncytial Virus (RSV) Infections - Pipeline by Ablynx NV, H1 2017
    Respiratory Syncytial Virus (RSV) Infections - Pipeline by ADMA Biologics Inc, H1 2017
    Respiratory Syncytial Virus (RSV) Infections - Pipeline by Agilvax Inc, H1 2017
    Respiratory Syncytial Virus (RSV) Infections - Pipeline by Amarillo Biosciences Inc, H1 2017
    Respiratory Syncytial Virus (RSV) Infections - Pipeline by Anima Biotech Ltd, H1 2017
    Respiratory Syncytial Virus (RSV) Infections - Pipeline by Aridis Pharmaceuticals LLC, H1 2017
    Respiratory Syncytial Virus (RSV) Infections - Pipeline by Artificial Cell Technologies Inc, H1 2017
    Respiratory Syncytial Virus (RSV) Infections - Pipeline by AstraZeneca Plc, H1 2017
    Respiratory Syncytial Virus (RSV) Infections - Pipeline by Aviragen Therapeutics Inc, H1 2017
    Respiratory Syncytial Virus (RSV) Infections - Pipeline by Bavarian Nordic A/S, H1 2017
    Respiratory Syncytial Virus (RSV) Infections - Pipeline by Celltrion Inc, H1 2017
    Respiratory Syncytial Virus (RSV) Infections - Pipeline by Curevac AG, H1 2017
    Respiratory Syncytial Virus (RSV) Infections - Pipeline by DBV Technologies SA, H1 2017
    Respiratory Syncytial Virus (RSV) Infections - Pipeline by Emergent BioSolutions Inc, H1 2017
    Respiratory Syncytial Virus (RSV) Infections - Pipeline by Enanta Pharmaceuticals Inc, H1 2017
    Respiratory Syncytial Virus (RSV) Infections - Pipeline by Evec Inc, H1 2017
    Respiratory Syncytial Virus (RSV) Infections - Pipeline by F. Hoffmann-La Roche Ltd, H1 2017
    Respiratory Syncytial Virus (RSV) Infections - Pipeline by Gene Techno Science Co Ltd, H1 2017
    Respiratory Syncytial Virus (RSV) Infections - Pipeline by GenVec Inc, H1 2017
    Respiratory Syncytial Virus (RSV) Infections - Pipeline by Gilead Sciences Inc, H1 2017
    Respiratory Syncytial Virus (RSV) Infections - Pipeline by GlaxoSmithKline Plc, H1 2017
    Respiratory Syncytial Virus (RSV) Infections - Pipeline by Globavir Biosciences Inc, H1 2017
    Respiratory Syncytial Virus (RSV) Infections - Pipeline by Humabs BioMed SA, H1 2017
    Respiratory Syncytial Virus (RSV) Infections - Pipeline by iBio Inc, H1 2017
    Respiratory Syncytial Virus (RSV) Infections - Pipeline by Immunovaccine Inc, H1 2017
    Respiratory Syncytial Virus (RSV) Infections - Pipeline by Immunwork Inc, H1 2017
    Respiratory Syncytial Virus (RSV) Infections - Pipeline by Inovio Pharmaceuticals Inc, H1 2017
    Respiratory Syncytial Virus (RSV) Infections - Pipeline by Johnson & Johnson, H1 2017
    Respiratory Syncytial Virus (RSV) Infections - Pipeline by Karyopharm Therapeutics Inc, H1 2017
    Respiratory Syncytial Virus (RSV) Infections - Pipeline by Kineta Inc, H1 2017
    Respiratory Syncytial Virus (RSV) Infections - Pipeline by mAbxience SA, H1 2017
    Respiratory Syncytial Virus (RSV) Infections - Pipeline by MedImmune LLC, H1 2017
    Respiratory Syncytial Virus (RSV) Infections - Pipeline by Medivir AB, H1 2017
    Respiratory Syncytial Virus (RSV) Infections - Pipeline by Merck & Co Inc, H1 2017
    Respiratory Syncytial Virus (RSV) Infections - Pipeline by Mucosis BV, H1 2017
    Respiratory Syncytial Virus (RSV) Infections - Pipeline by Mymetics Corp, H1 2017
    Respiratory Syncytial Virus (RSV) Infections - Pipeline by NanoBio Corp, H1 2017
    Respiratory Syncytial Virus (RSV) Infections - Pipeline by Navigen Inc, H1 2017
    Respiratory Syncytial Virus (RSV) Infections - Pipeline by Novavax Inc, H1 2017
    Respiratory Syncytial Virus (RSV) Infections - Pipeline by Phoenix Biotechnology Inc, H1 2017
    Respiratory Syncytial Virus (RSV) Infections - Pipeline by Profectus BioSciences Inc, H1 2017
    Respiratory Syncytial Virus (RSV) Infections - Pipeline by Pulmocide Ltd, H1 2017
    Respiratory Syncytial Virus (RSV) Infections - Pipeline by Regeneron Pharmaceuticals Inc, H1 2017
    Respiratory Syncytial Virus (RSV) Infections - Pipeline by ReViral Ltd, H1 2017
    Respiratory Syncytial Virus (RSV) Infections - Pipeline by Romark Laboratories LC, H1 2017
    Respiratory Syncytial Virus (RSV) Infections - Pipeline by Sanofi, H1 2017
    Respiratory Syncytial Virus (RSV) Infections - Pipeline by Spring Bank Pharmaceuticals Inc, H1 2017
    Respiratory Syncytial Virus (RSV) Infections - Pipeline by Takeda Pharmaceutical Company Ltd, H1 2017
    Respiratory Syncytial Virus (RSV) Infections - Pipeline by TechnoVax Inc, H1 2017
    Respiratory Syncytial Virus (RSV) Infections - Pipeline by Themis Bioscience GmbH, H1 2017
    Respiratory Syncytial Virus (RSV) Infections - Pipeline by Vault Pharma Inc, H1 2017
    Respiratory Syncytial Virus (RSV) Infections - Pipeline by Vaxart Inc, H1 2017
    Respiratory Syncytial Virus (RSV) Infections - Pipeline by VBI Vaccines Inc, H1 2017
    Respiratory Syncytial Virus (RSV) Infections - Pipeline by Virometix AG, H1 2017
    Respiratory Syncytial Virus (RSV) Infections - Pipeline by Visterra Inc, H1 2017
    Respiratory Syncytial Virus (RSV) Infections - Pipeline by VLP Biotech Inc, H1 2017
    Respiratory Syncytial Virus (RSV) Infections - Dormant Projects, H1 2017
    Respiratory Syncytial Virus (RSV) Infections - Dormant Projects, H1 2017 (Contd..1) , H1 2017
    Respiratory Syncytial Virus (RSV) Infections - Dormant Projects, H1 2017 (Contd..2) , H1 2017
    Respiratory Syncytial Virus (RSV) Infections - Discontinued Products, H1 2017

    List of Figures

    Number of Products under Development for Respiratory Syncytial Virus (RSV) Infections, H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products under Development by Universities/Institutes, H1 2017
    Number of Products by Targets, H1 2017
    Number of Products by Stage and Targets, H1 2017
    Number of Products by Top 10 Mechanism of Actions, H1 2017
    Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
    Number of Products by Routes of Administration, H1 2017
    Number of Products by Stage and Routes of Administration, H1 2017
    Number of Products by Top 10 Molecule Types, H1 2017
    Number of Products by Stage and Top 10 Molecule Types, H1 2017
    Abivax SA
    Ablynx NV
    ADMA Biologics Inc
    Agilvax Inc
    Amarillo Biosciences Inc
    Anima Biotech Ltd
    Aridis Pharmaceuticals LLC
    Artificial Cell Technologies Inc
    AstraZeneca Plc
    Aviragen Therapeutics Inc
    Bavarian Nordic A/S
    Celltrion Inc
    Curevac AG
    DBV Technologies SA
    Emergent BioSolutions Inc
    Enanta Pharmaceuticals Inc
    Evec Inc
    F. Hoffmann-La Roche Ltd
    Gene Techno Science Co Ltd
    GenVec Inc
    Gilead Sciences Inc
    GlaxoSmithKline Plc
    Globavir Biosciences Inc
    Humabs BioMed SA
    iBio Inc
    Immunovaccine Inc
    Immunwork Inc
    Inovio Pharmaceuticals Inc
    Johnson & Johnson
    Karyopharm Therapeutics Inc
    Kineta Inc
    mAbxience SA
    MedImmune LLC
    Medivir AB
    Merck & Co Inc
    Mucosis BV
    Mymetics Corp
    NanoBio Corp
    Navigen Inc
    Novavax Inc
    Phoenix Biotechnology Inc
    Profectus BioSciences Inc
    Pulmocide Ltd
    Regeneron Pharmaceuticals Inc
    ReViral Ltd
    Romark Laboratories LC
    Sanofi
    Spring Bank Pharmaceuticals Inc
    Takeda Pharmaceutical Company Ltd
    TechnoVax Inc
    Themis Bioscience GmbH
    Vault Pharma Inc
    Vaxart Inc
    VBI Vaccines Inc
    Virometix AG
    Visterra Inc
    VLP Biotech Inc

    Request for Sample

    Report Url http://www.reportsweb.com//respiratory-syncytial-virus-infections-pipeline-review-h1-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url http://www.reportsweb.com//respiratory-syncytial-virus-infections-pipeline-review-h1-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url http://www.reportsweb.com//respiratory-syncytial-virus-infections-pipeline-review-h1-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments